Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
News Feb 01, 2008
Millennium Pharmaceuticals, Inc. and Harvard Medical School's Office of Technology Development have announced a collaboration agreement to pursue a research program in the area of protein homeostasis, an emerging and expanding field of cancer biology.
Under the terms of the agreement, Harvard has granted Millennium a license to certain invention from the laboratory of Professor J. Wade Harper and the two institutions will jointly advance the program in this novel area of research over several years under a sponsored research agreement. Financial terms were not disclosed.
"Harvard Medical School's research initiatives in protein homeostasis, together with the demonstrated leadership of Millennium in this area, promises to advance our understanding of this important field and its role in regulating cancer cells," said Wade Harper, Ph.D., Bert and Natalie Vallee Professor of Molecular Pathology, Harvard Medical School. "We expect this collaboration to accelerate the important work the lab has accomplished to date."
Research has shown various pathways that regulate cellular protein homeostasis are linked to the pathologic properties of a broad range of cancers. The initial research-based agreement is focused on advancing knowledge in this evolving field over the course of three years.
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.